Skip to main content

Table 1 Patient demographics and characteristics

From: Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Patient No. ECOG PS Histological subtype Stage Primary site Metastatic site Previous lines of chemotherapy Response PFS (Months)
1 1 UPS IV Head Lung and bone 1 PR 5
2 1 UPS IV Extremities Lung and lymph nodes 1 PR 3.5
3 0 UPS IV Extremities Lung and bone 2 SD 3
4 0 UPS IV Neck Bone 2 SD 2.5
5 0 UPS IV Extremities Lung 2 PD 2
6 0 UPS IV Extremities Bone 2 PD 1.8
7 1 UPS IV Extremities Lung 1 PD 1
8 1 Angiosarcoma IV Head Liver 2 CR 15
9 0 Angiosarcoma IV Trunk Bone 2 PR 7.8
10 1 Angiosarcoma IV Extremities Lung 2 PR 4
11 0 Angiosarcoma IV Extremities Lung 2 SD 4.5
12 0 Angiosarcoma IV Trunk Lung 2 PD 2
13 1 Epithelioid sarcoma IV Extremities Lung 2 PR 2.8
14 1 Epithelioid sarcoma IV Trunk Lung and lymph nodes 2 SD 3
15 1 Epithelioid sarcoma IV Trunk Lung 2 SD 2.8
16 0 Epithelioid sarcoma IV Extremities Lung 1 PD 1.8
17 1 Epithelioid sarcoma IV Extremities Lung and bone 2 PD 1.3
18 1 Fibrosarcoma IV Trunk Lung 2 PR 4.3
19 1 Fibrosarcoma IV Extremities Lung 2 SD 2.5
20 0 Fibrosarcoma IV Extremities Lung 1 PD 1.5
21 0 Fibrosarcoma IV Extremities Liver 3 PD 1.3
22 0 Synovial sarcoma IV Neck Lung 2 PD 1.8
23 0 Synovial sarcoma IV Extremities Lung 2 PD 1.5
24 1 Synovial sarcoma IV Trunk Lung 3 PD 1.5
25 0 Leiomyosarcoma IV Extremities Lung 2 SD 2.8
26 1 Leiomyosarcoma IV Trunk Liver 1 PD 1.3
27 0 Pleomorphic liposarcoma IV Extremities Lung 2 PD 1.8
28 1 Rhabdomyosarcoma IV Head Lung 1 PD 1.5
  1. The clinical and pathologic stages are expressed according to the American Joint Committee on Cancer (8th Edition) TNM staging. Tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1), and were categorized as CR Complete response, PR Partial response, SD Stable disease, or PD Progressive disease. PFS Progression-free survival was calculated from the date of the first nab-paclitaxel plus PD-1 inhibitor treatment until the date of documented progression
  2. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, UPS Undifferentiated pleomorphic sarcoma
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us